InvestorsHub Logo
Followers 15
Posts 1318
Boards Moderated 0
Alias Born 07/27/2015

Re: JWC3 post# 280011

Tuesday, 11/03/2020 2:50:23 AM

Tuesday, November 03, 2020 2:50:23 AM

Post# of 462869
LB25 - ANAVEX®2-73 (blarcamesine) Currently in Phase 2b/3 Early Alzheimer’s Disease (AD): Analysis of Cognitive Outcome Measures Relevant in AD of Double-blind, Multicenter, Placebo-controlled Phase 2 Clinical Trial in 132 Patients with Parkinson’s Disease Dementia
Dag Aarsland (1), Jaime Kulisevsky Bojarski (2), Mohammad Afshar (3), Coralie Williams (3), Frederic Parmentier (3), Martin
(1)King’s College - London (United Kingdom); (2)University of Barcelona - Barcelona (Spain); (3)Ariana Pharma - Paris (France); (4)Anavex Life Sciences - New York, NY (United States)
Kindermans (3), Tayo Fadiran (4), Andy Mattai (4), Christopher U Missling (4), Walter E Kaufmann (4)

https://www.ctad-alzheimer.com/files/files/DIGITALprogram_CTAD2020_23oct.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News